Asset Details
Do you wish to reserve the book?
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4–5 chronic kidney disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4–5 chronic kidney disease
Do you wish to request the book?
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4–5 chronic kidney disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4–5 chronic kidney disease
2024
Overview
Background
Blood pressure (BP) control is an important factor in the management of chronic kidney disease (CKD). Several studies have shown that BP in many patients with CKD remained uncontrolled even with multiple medications. Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNI), has been newly approved for treating hypertension in Japan. However, the renoprotective effects remain unclear, particularly in patients with advanced CKD. Here, we investigated the effects on proteinuria of this ARNI in patients with stage 4–5 CKD.
Methods
We retrospectively collected data from outpatients with stage 4–5 CKD who started ARNI from January until December 2023. The primary outcome was the change in urine protein creatinine ratio (UPCR) at 6 months after ARNI initiation. Secondary outcomes were systolic and diastolic BP, estimated glomerular filtration rate (eGFR), serum potassium, and serum uric acid (UA). We analyzed factors associated with 50% UPCR reduction by multivariate analysis.
Results
In total, 47 patients were analyzed. ARNI reduced UPCR from 2.14 g/gCr (interquartile range; 1.09–2.91) to 1.05 g/gCr (0.42–1.95;
p
< 0.001). Systolic BP fell from 150.0 mmHg (139.5–160.0) to 134.0 mmHg (124.5–140.0;
p
< 0.001). No significant changes in eGFR, serum potassium, and serum uric acid were observed, except for a slight decrease in eGFR among patients with conversion from a renin–angiotensin system inhibitor to ARNI. In multivariate regression analysis, higher systolic BP (per 10-mmHg increase) was significantly associated with reduced proteinuria (odds ratio 2.51, 95% confidence interval 1.35–4.66;
p
= 0.004).
Conclusions
ARNI reduced proteinuria in patients with stage 4–5 CKD, particularly for those with uncontrolled hypertension.
Publisher
Springer Nature Singapore,Springer Nature B.V
Subject
/ Aminobutyrates - therapeutic use
/ Angiotensin Receptor Antagonists - therapeutic use
/ Biphenyl Compounds - therapeutic use
/ Blood Pressure - drug effects
/ Epidermal growth factor receptors
/ Female
/ Glomerular Filtration Rate - drug effects
/ Humans
/ Hypertension - complications
/ Hypertension - physiopathology
/ Male
/ Medicine
/ Neprilysin - antagonists & inhibitors
/ Renal Insufficiency, Chronic - complications
/ Renal Insufficiency, Chronic - drug therapy
/ Renal Insufficiency, Chronic - physiopathology
/ Renal Insufficiency, Chronic - urine
/ Renin
/ Tetrazoles - therapeutic use
/ Urology
